- The disease
- Menopausal vasomotor symptoms, commonly called hot flushes, are episodes of sudden heat sensation, flushing, and sweating that occur during and after the menopause transition. They are caused by hormonal changes, primarily a decline in estrogen, that affect the body's temperature-regulation pathways. Hot flushes affect a substantial proportion of women going through menopause and can persist for several years. They represent one of the most common reasons women seek medical treatment during this life stage.
- What the asset is trying to do
- Lenzetto is a transdermal estradiol spray, meaning it delivers the hormone estradiol through the skin rather than via a tablet or patch. Estradiol is the primary form of estrogen naturally produced by the ovaries, and replacing it at low doses is an established approach to reducing hot flushes. The spray format is designed to allow precise dosing and convenient application compared with some other delivery methods. Acrux's formulation uses the company's own transdermal drug delivery technology.
- Efficacy benchmarks in this setting
- Approved transdermal estradiol products have been studied in randomised controlled trials for menopausal vasomotor symptoms. As a reference point, the US prescribing information for Evamist (estradiol transdermal spray, the US equivalent of Lenzetto) reports reductions in the frequency and severity of moderate-to-severe hot flushes compared with placebo in a pivotal Phase 3 trial (per Evamist US prescribing information). Other approved estradiol therapies, including patches and gels, have similarly demonstrated statistically significant reductions in hot flush frequency in placebo-controlled trials cited in their respective prescribing information. Because Lenzetto is already an approved product, its clinical evidence base is established; early-stage figures from investigational assets in this space are not statistically comparable to approved product data.
- Commercial context
- Lenzetto is a commercially approved product, not an investigational asset. It is marketed in Europe and other international markets by Gedeon Richter under a licensing arrangement with Acrux. The equivalent product in the United States is marketed as Evamist. On 29 May 2026, Acrux announced a licensing agreement for Lenzetto in Australia for AUD 5.4 million (per ASX announcement, 29 May 2026). Acrux raised AUD 1.6 million via a share placement announced on 11 May 2026 (per ASX announcement, 11 May 2026). Lenzetto appears to be the company's primary disclosed commercial asset based on available ASX announcements.